RNS Number: 8094H
Sareum Holdings PLC
15 November 2007
 
Sareum Holdings plc
AGM Statement
 
At the Company's annual general meeting held today, the following resolutions were passed unanimously by shareholders on a show of hands.
 
The proxy votes received prior to the meeting on each resolution were as follows:
 

 

ORDINARY RESOLUTIONS
Votes
For
Discretion
Votes
Against
Votes
Withheld
1.         To receive and adopt the Directors’ report and financial statements for the year ended 30 June 2007.
 
8,724,070
 
221,058
 
0
 
0
 
97.53%
 
2.47%
 
0%
 
0%
2.         To receive and adopt the Remuneration Committee report for the year ended 30 June 2007.
 
8,679,070
 
266,058
 
0
 
0
 
97.03%
 
2.97%
 
0%
 
0%
3.         To re-elect Dr Paul Harper as Director.
 
8,724,070
 
221,058
 
0
 
0
 
97.53%
 
2.47%
 
0%
 
0%
4.         To re-elect Mr Giorgio Reggiani as Director.
 
8,576,070
 
366,058
 
3,000
 
0
 
95.88%
 
4.09%
 
0.03%
 
0%
5.       To re-appoint Shipleys LLP as auditors and authorise the Directors to fix their remuneration.
 
8,721,070
 
221,058
 
3,000
 
0
 
97.50%
 
2.47%
 
0.03%
 
0%
6.       To authorise Directors for the purposes of section 80 of the Companies Act 1985 (the Act) to allot relevant securities (within the meaning of that section) up to an aggregate nominal amount of £90,000.
 
 
 
8,531,070
 
 
366,058
 
 
48,000
 
 
0
 
95.37%
 
4.09%
 
0.54%
 
0%
 

 

SPECIAL RESOLUTIONS
 
Votes
For
Discretion
Votes
Against
Votes
Withheld
7.       Subject to the passing of resolution 6, to authorise Directors, in accordance with section 95 of the Act, to allot equity securities (as defined in section 94 of the Act) wholly for cash up to an aggregate nominal amount of £50,000.
.
 
8,531,070
 
321,058
 
93,000
 
0
 
95.37%
 
3.59%
 
1.04%
 
0%
8.         To authorise the Company to send or supply documents or information to shareholders by making them available on the Company’s website or other electronic means.
 
 
8,549,070
 
266,058
 
130,000
 
0
 
95.58%
 
2.97%
 
1.45%
 
0%
 
For further information please contact:
 

 

Sareum Holdings
+44 (0) 1223 497700
Tim Mitchell, Chief Executive Officer
 
 
 
Buchanan Communications
+44 (0) 20 7466 5000
Tim Anderson, Mary-Jane Johnson
 
Notes for editors:
About Sareum Holdings plc
Sareum Holdings plc is a structure-based drug discovery business headquartered in Cambridge, UK. Sareum Limited was formed in August 2003 to discover new drugs for the treatment of cancer and to provide a range of drug discovery services to the pharmaceutical industry. Sareum’s unique approach aims to halve the time it takes to discover new drug candidates.
 
A structure-based approach to drug discovery relies on knowledge of the three-dimensional structure of the proteins that cause disease. Once the structure is known, potential drugs are designed to ‘lock-in’ to the protein with the aim of reversing or arresting a disease’s progression. Knowledge of the structure of the potential drugs and how they ‘lock-in’ to the protein permits the best potential drug to be discovered. Determining structure is a complex task and requires leading-edge equipment and experienced staff. Sareum’s approach to structure determination is to produce multiple recombinant proteins primarily through a baculovirus expression system and to determine their structure using x-ray crystallography.
 
When the structure is determined, the Company’s innovative Template Screening platform is used to identify novel chemical starting material designed to interact with the target protein. Sareum then uses its high-throughput medicinal chemistry platform to rapidly optimise these molecules and develop the most promising into potential drug candidates.
 
Sareum provides its specialist drug discovery capabilities to partners in the pharmaceutical and biotechnology industries. The Company aims to successfully deliver: Programmes for complete gene-to-candidate structure-based discovery; projects to accelerate or improve the productivity of specific activities; and drug candidates for licensing at the Phase I or Phase II clinical trials stage.
 
Sareum joined the AIM market of the London Stock Exchange in October 2004 and trades under the symbol SAR. For further information, please visit www.sareum.co.uk